메지온

140410KOSDAQ자연과학 및 공학 연구개발업

40.0 / 100

Reference Date: 2026-06-10

Financial Score15.0 / 40

News Sentiment15.0 / 25

Momentum3.0 / 20

Disclosure7.0 / 15

AI Analysis: the debt ratio is low with sound financial health but Revenue is on a declining trend. Plunged 28.2% over the past month, and news sentiment is negative.

Company InformationBased on 2025 Annual Report

Business Overview

Meizon is a pharmaceutical company established in 2002, focusing on global new drug development for various diseases, including erectile dysfunction and single-ventricle syndrome treatments. Although it submitted a New Drug Application (NDA) to the FDA for a single-ventricle syndrome treatment in 2021, the application was temporarily withdrawn following a request for additional clinical trials, and the company is now proceeding with the additional trial process.

Number of Employees

18people

Average Salary

63.7M KRW

Score Calculation Basis

Detailed Financial Score

PER

—Industry Average 62.704.0Point

PBR

—Industry Average 3.243.5Point

ROE

-110.44Industry Average -32.093.5Point

3.4x industry avg (excellent)

Debt Ratio

7.31Industry Average 7.314.0Point

In line with industry avg

Trend 2023~20250.0 / 10 points

Revenue Growth Rate

0.0 / 3

Avg ▼40.5% (2-year basis)

Operating Profit Growth Rate

0.0 / 3

Avg ▼8.0% (2-year basis)

ROE Trend

0.0 / 4

Avg ROE -58.6% (declining, 3yr)

Detailed News Sentiment

7 totalPositive 1Neutral 3Negative 3Average Sentiment Score 60

Positive
메지온, 4·5회차 CB 콜옵션 행사…50억 규모 취득 예정
메지온의 CB 콜옵션 행사로 자금 조달 성공, 기업 성장 기대감 증가.
Neutral
삼부토건 손자, LG家 윤관 상대 '2억원 대여금 소송' 2심 일부승소
LG 가문과의 소송 결과가 일부 인정되었으나, 메지온 주식에 직접적인 영향은 제한적임.
Negative
LG家 장녀 부부 '미공개 정보 이용' 항소심 시작…검찰, 직관 검토
LG 가족 관련 미공개 정보 이용 혐의로 인한 항소심 시작으로 메지온 주가에 부정적 영향 예상.

Detailed Momentum

52-week position1.0Point

Near 52w low (18%, downtrend)

Current 62,000Won52-week high 172,70052-week low 36,450

1-month return0.0Point

1m -28.24% (strong drop)

Volume trend2.0Point

Volume decreasing

Detailed Disclosure

5 totalPositive 0Neutral 4Negative 1

Neutral주요사항보고서(자기전환사채만기전취득결정)2026-05-22
Neutral주요사항보고서(자기전환사채만기전취득결정)2026-05-22
Negative소송등의제기ㆍ신청(일정금액이상의청구)2026-05-21
Neutral분기보고서 (2026.03)2026-05-15
Neutral증권발행결과(자율공시) (제6회차 CB)2026-05-12